<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37809592</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model.</ArticleTitle><Pagination><StartPage>e19605</StartPage><MedlinePgn>e19605</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e19605</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2023.e19605</ELocationID><Abstract><AbstractText>Long COVID has become a significant global health and economic burden, yet there are currently no established methods or diagnostic tools to identify which patients might benefit from specific treatments. One of the major pathophysiological factors contributing to Long COVID is the presence of hypercoagulability; this results in insoluble amyloid microclots that are resistant to fibrinolysis. Our previous research using fluorescence microscopy has demonstrated a significant amyloid microclot load in Long COVID patients. However, this approach lacked the elements of statistical robustness, objectivity, and rapid throughput. In the current study, we have used imaging flow cytometry for the first time to show a significantly increased concentration and size of these microclots. We identified notable variations in size and fluorescence between microclots in Long COVID and those of controls even using a 20&#xd7; objective. By combining cell imaging and the high-event-rate and full-sample analysis nature of a conventional flow cytometer, imaging flow cytometry can eliminate erroneous results and increase accuracy in gating and analysis beyond what pure quantitative measurements from conventional flow cytometry can provide. Although imaging flow cytometry was used in our study, our results suggest that the signals indicating the presence of microclots should be easily detectable using a conventional flow cytometer. Flow cytometry is a more widely available technique than fluorescence microscopy and has been used in pathology laboratories for decades, rendering it a potentially more suitable and accessible method for detecting microclots in individuals suffering from Long COVID or conditions with similar pathology, such as myalgic encephalomyelitis.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laubscher</LastName><ForeName>Gert Jacobus</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Mediclinic Stellenbosch, Stellenbosch, 7600, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>M Asad</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Respiratory Medicine, Manchester University Hospitals, Wythenshawe Hospital, Manchester, M23 9LT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kell</LastName><ForeName>Douglas B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, L69 7ZB, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Kemitorvet 200, 2800, Kgs Lyngby, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pretorius</LastName><ForeName>Etheresia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Stellenbosch, Private Bag X1, Matieland, 7602, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, L69 7ZB, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyloid microclots</Keyword><Keyword MajorTopicYN="N">Fluorescence</Keyword><Keyword MajorTopicYN="N">Imaging flow cytometry</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Competing interests EP is a director of Biocode Technologies; ST is the COO at Biocode Technologies. The other authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37809592</ArticleId><ArticleId IdType="pmc">PMC10558872</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2023.e19605</ArticleId><ArticleId IdType="pii">S2405-8440(23)06813-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Astin R., Banerjee A., Baker M.R., Dani M., Ford E., Hull J.H., et al. Long COVID: mechanisms, risk factors and recovery. Exp. Physiol. 2023;108(1):12&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10103775</ArticleId><ArticleId IdType="pubmed">36412084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem. J. 2022;479(4):537&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Pretorius E. The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochem. J. 2022;479(16):1653&#x2013;1708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9484810</ArticleId><ArticleId IdType="pubmed">36043493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A., Vlok M., Turner S., Venter C., Laubscher G.J., Kell D.B., et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc. Diabetol. 2022;21(1):190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B. Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovasc. Diabetol. 2020;19(1):193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C., Bezuidenhout J.A., Laubscher G.J., Steenkamp J., et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20(1):172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Naidoo C.A., Usher T.J., Kruger A., Venter C., Laubscher G.J., et al. Increased levels of inflammatory molecules in blood of Long COVID patients point to thrombotic endotheliitis. medRxiv. 2022:2022. 10.13.22281055.</Citation><ArticleIdList><ArticleId IdType="pubmed">37207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., Safarpour A., Lunz Trujillo K., Simonson M.D., et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw. Open. 2022;5(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Science G.A.O.  2022. Technology Assessment, and Analytics: SCIENCE &amp; TECH SPOTLIGHT: LONG COVID.https://www.gao.gov/assets/gao-22-105666.pdf</Citation></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastenhuber E.R., Mercadante M., Nilsson-Payant B., Johnson J.L., Jaimes J.A., Muecksch F., et al. Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. Elife. 2022:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942469</ArticleId><ArticleId IdType="pubmed">35294338</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S., Hammarstr&#xf6;m P. Amyloidogenesis of SARS-CoV-2 spike protein. J. Am. Chem. Soc. 2022;144(20):8945&#x2013;8950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9136918</ArticleId><ArticleId IdType="pubmed">35579205</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M., Ngoepe M., Laubscher G.J., Lourens P.J., et al. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot formation in COVID-19. Biosci. Rep. 2021;41(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Bester J., Kell D.B. A bacterial component to alzheimer's-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis. 2016;53(4):1237&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5325058</ArticleId><ArticleId IdType="pubmed">27340854</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Page M.J., Hendricks L., Nkosi N.B., Benson S.R., Kell D.B. Both lipopolysaccharide and lipoteichoic acids potently induce anomalous fibrin amyloid formation: assessment with novel Amytracker&#x2122; stains. J. R. Soc. Interface. 2018;15(139)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5832738</ArticleId><ArticleId IdType="pubmed">29445039</ArticleId></ArticleIdList></Reference><Reference><Citation>Althaus K., Marini I., Zlamal J., Pelzl L., Singh A., H&#xe4;berle H., et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137(8):1061&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7791311</ArticleId><ArticleId IdType="pubmed">33512415</ArticleId></ArticleIdList></Reference><Reference><Citation>Fard M.B., Fard S.B., Ramazi S., Atashi A., Eslamifar Z. Thrombosis in COVID-19 infection: role of platelet activation-mediated immunity. Thromb. J. 2021;19(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8380864</ArticleId><ArticleId IdType="pubmed">34425822</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemostasis. 2021;19(10):2546&#x2013;2553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobler C., Maphumulo S.C., Grobbelaar L.M., Bredenkamp J.C., Laubscher G.J., Lourens P.J., et al. Covid-19: the rollercoaster of fibrin(ogen), D-dimer, von willebrand factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes. Int. J. Mol. Sci. 2020;21(14)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403995</ArticleId><ArticleId IdType="pubmed">32708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Yang Y., Li Y., Wang Z., Ma F., Luo R., et al. Platelets mediate inflammatory monocyte activation by SARS-CoV-2 Spike protein. J. Clin. Investig. 2021:e150101. doi: 10.1172/JCI150101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI150101</ArticleId><ArticleId IdType="pmc">PMC8843740</ArticleId><ArticleId IdType="pubmed">34964720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchi&#xe9; A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 2021;21(5):319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Kruger A., Venter C., Burger E.M., Laubscher G.J., Maponga T.G., et al. Relative hypercoagulopathy of the SARS-CoV-2 beta and delta variants when compared to the less severe omicron variants is related to TEG parameters, the extent of fibrin amyloid microclots, and the severity of clinical illness. Semin. Thromb. Hemost. 2022;48(7):858&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">36174604</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubscher G.J., Lourens P.J., Venter C., Kell D.B., Pretorius E. TEG&#xae;, microclot and platelet mapping for guiding early management of severe COVID-19 coagulopathy. J. Clin. Med. 2021;10(22)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621180</ArticleId><ArticleId IdType="pubmed">34830660</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Venter C., Laubscher G.J., Kotze M.J., Oladejo S.O., Watson L.R., et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC) Cardiovasc. Diabetol. 2022;21(1):148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter C., Bezuidenhout J.A., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B., et al. Erythrocyte, platelet, serum ferritin, and P-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19. Int. J. Mol. Sci. 2020;21(21)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662625</ArticleId><ArticleId IdType="pubmed">33153161</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey H.M., Kell D.B. Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses. Microbiol. Rev. 1996;60(4):641&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC239459</ArticleId><ArticleId IdType="pubmed">8987359</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinnon K.M. Flow cytometry: an overview. Curr. Protoc. Im. 2018;120 5.1.-5.1.11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939936</ArticleId><ArticleId IdType="pubmed">29512141</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S., Khan M.A., Putrino D., Woodcock A., Kell D.B., Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol. Metabol. 2023;34(6):321&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113134</ArticleId><ArticleId IdType="pubmed">37080828</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann D.M., Whettlock E.M., Liu S., Arachchillage D.J., Boyton R.J. The immunology of long COVID. Nat. Rev. Immunol. 2023</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavrakis S., Holzner G., Choo J., deMello A. High-throughput microfluidic imaging flow cytometry. Curr. Opin. Biotechnol. 2019;55:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">30118968</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro H.M. John Wiley &amp; Sons, Inc.; 2003. Pratical Flow Cytometry.</Citation></Reference><Reference><Citation>Rees P., Summers H.D., Filby A., Carpenter A.E., Doan M. Imaging flow cytometry. Nature Reviews Methods Primers. 2022;2(1):86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10468826</ArticleId><ArticleId IdType="pubmed">37655209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig H., Rees P., Blasi T., Kamentsky L., Hung J., Dao D., et al. An open-source solution for advanced imaging flow cytometry data analysis using machine learning. Methods. 2017;112:201&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5231320</ArticleId><ArticleId IdType="pubmed">27594698</ArticleId></ArticleIdList></Reference><Reference><Citation>Doan M., Vorobjev I., Rees P., Filby A., Wolkenhauer O., Goldfeld A.E., et al. Diagnostic potential of imaging flow cytometry. Trends Biotechnol. 2018;36(7):649&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pubmed">29395345</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>